

No. 31A(1)/Stent/2017/Div.III/NPPA
Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceuticals Pricing Authority

3rd& 5th Floor,
YMCA Cultural Centre Building,
1, Jai Singh Road, New Delhi - 110 001

Dated, the 29th September, 2017

OFFICE MEMORANDUM

Subject: Withdrawal of order issued by NPPA dated 25th September, 2017 for discontinuation of Xience Alpine brand of coronary stent under Para 21(2) of DPCO, 2013 - regarding.

The undersigned is directed to refer to NPPA's OM of even number dated 25th September, 2017 conveying the decision of the Authority under Para 21(2) to allow withdrawal of Xience Alpine brand of coronary stent in a period of one year from the date of issue of public notice by M/s. Abbott Healthcare Pvt. Ltd.

2. Subsequent to the issue of the above OM, the Department of Pharmaceuticals vide Order No.31026/05/2017-Pricing dated 27th September, 2017 invoked the powers of Section 3 (i) of DPCO,2013 and directed companies manufacturing coronary stents to maintain uninterrupted supply of coronary stents for three months from the date of notification. Therefore, the order dated 27th September, 2017 issued by the Department of Pharmaceuticals supersedes the OM dated 25th September, 2017 issued by NPPA and makes it null and void.

3. You are therefore hereby directed to follow the order dated 27th September, 2017 issued by the Department of Pharmaceuticals:-

- i. to maintain production/import/supply of the coronary stents,
- ii. to submit a weekly report on coronary stents produced and distributed and also to submit a weekly production plan for the next week to NPPA and DGCI;



(R. Nihal Pedric)
Deputy Director

To:
The Managing Director/CEO,
M/s. Abbott Healthcare Pvt. Ltd,
Floor 18, Godrej BKC,
Near MCA Club, Bandra East, Mumbai - 400 051

Copy to -

1. Secretary, Department of Pharmaceuticals.
2. Secretary, Ministry of Health & Family Welfare.
3. Drug Controller General of India.
4. All State Drug Controllers.